TLDR Citi raised its price target on NEM to $150 from $118, reiterating a Buy rating Bernstein upgraded NEM to Outperform and lifted its target to $157 from $121TLDR Citi raised its price target on NEM to $150 from $118, reiterating a Buy rating Bernstein upgraded NEM to Outperform and lifted its target to $157 from $121

Newmont (NEM) Stock Gets a Boost as Citi and Bernstein Lift Targets by Up to 30%

2026/03/09 23:30
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Citi raised its price target on NEM to $150 from $118, reiterating a Buy rating
  • Bernstein upgraded NEM to Outperform and lifted its target to $157 from $121, citing a bullish gold outlook
  • NEM beat earnings estimates in each of the last four quarters, with a Q4 EPS surprise of +24.14%
  • Consensus EPS estimate for the current fiscal year is $8.65, up 25.5% year-over-year
  • NEM has returned +0.8% over the past month, outperforming the S&P 500’s -2.7% drop in the same period

Newmont’s gold mineral reserves fell to 118.2 million attributable ounces at end of 2025, down from 134.1 million the year before, mainly due to asset sales. The company still holds 12.5 million tonnes of copper reserves and 442 million ounces of silver reserves.


NEM Stock Card
Newmont Corporation, NEM

In Q4, Newmont posted revenues of $6.82 billion, a 20.6% jump year-over-year. EPS came in at $2.52, up from $1.40 a year ago.

Both numbers topped estimates. Revenue beat the consensus of $6.06 billion by 12.58%, and EPS came in 24.14% above expectations.

The company has now beaten consensus EPS estimates in each of the last four quarters. It has also topped revenue estimates across that same stretch.

Looking ahead, analysts expect Q1 EPS of $1.91, a 52.8% rise from the same quarter last year. The consensus estimate for that figure has moved up 10.4% over the past 30 days.

For the full year, the consensus EPS estimate sits at $8.65, reflecting 25.5% growth over the prior year. That estimate has climbed 11.2% over the past month alone.

Analyst Price Target Upgrades

On March 3, Citi raised its price target on NEM to $150 from $118, keeping its Buy rating in place.

Bernstein moved a week earlier, on February 27, upgrading the stock from Market Perform to Outperform and raising its target to $157 from $121.

Bernstein pointed to a bullish view on gold prices as the main driver. The firm also flagged a new CEO with a clear agenda, what it called achievable guidance, and an improving relationship with Newmont’s largest joint venture partner.

Zacks Rank and Valuation

Zacks currently rates NEM as a #1 Strong Buy. The rank is driven by the size and direction of recent earnings estimate revisions.

On valuation, Newmont scores a C in the Zacks Value Style Score system, meaning it’s trading roughly in line with its peers — not cheap, but not stretched either.

Over the past month, NEM returned +0.8%, while the S&P 500 dropped 2.7%. The Zacks Mining – Gold industry gained 4.6% over the same stretch.

For the current quarter, the revenue consensus stands at $5.87 billion, which would be a 17.2% increase year-over-year. Full-year revenue estimates are $24.01 billion and $27.65 billion for fiscal 2025 and 2026 respectively.

The post Newmont (NEM) Stock Gets a Boost as Citi and Bernstein Lift Targets by Up to 30% appeared first on CoinCentral.

Market Opportunity
Bullish Degen Logo
Bullish Degen Price(BULLISH)
$0.00393
$0.00393$0.00393
+10.86%
USD
Bullish Degen (BULLISH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.